(Q33628487)

28 July 2017

A randomised controlled study of bromocriptine versus levodopa in previously untreated Parkinsonian patients: a 3 year follow-up (English)

1 reference

28 July 2017

1 reference

1 reference

Montastruc JL

1

1 reference

28 July 2017

Rascol O

series ordinal

2

1 reference

28 July 2017

Rascol A

series ordinal

3

1 reference

28 July 2017

language of work or name

English

0 references

publication date

1 June 1989

1 reference

Journal of Neurology, Neurosurgery and Psychiatry

28 July 2017

1 reference

28 July 2017

52

1 reference

28 July 2017

6

1 reference

28 July 2017

773-775

1 reference

Parkinsonism: onset, progression, and mortality

28 July 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1032031

Combined bromocriptine-levodopa therapy early in Parkinson's disease.

14 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1032031

Bromocriptine in Parkinson disease

14 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1032031

Bromocriptine: long-term low-dose therapy in Parkinson's disease.

14 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1032031

Chronic treatment with L-DOPA, but not bromocriptine induces dyskinesia in MPTP-parkinsonian monkeys. Correlation with [3H]spiperone binding.

14 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1032031

Behavioral and biochemical evidence for a different effect of repeated administration of L-dopa and bromocriptine on denervated versus non-denervated striatal dopamine receptors.

14 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1032031

Bromocriptine in parkinsonism. A long-term study

14 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1032031

Long-term treatment of Parkinson's disease with bromocriptine

14 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1032031

Ergot Derivatives for Parkinsonism

14 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1032031

International symposium on early dopamine agonist therapy of Parkinson's disease

14 July 2018

1 reference

12 December 2020

[Bromocriptine as the 1st treatment of Parkinson's disease. Long term results]

1 reference

12 December 2020

1 reference

12 December 2020

Bromocriptine: problems with low-dose de novo therapy in Parkinson's disease

1 reference

12 December 2020

Bromocriptine and the clinical spectrum of Parkinson's disease

1 reference

12 December 2020

A comparison of bromocriptine (Parlodel) and levodopa-carbidopa (Sinemet) for treatment of "de novo" Parkinson's disease patients

1 reference

12 December 2020

Identifiers

DOI

10.1136/JNNP.52.6.773

1 reference

28 July 2017

1 reference

28 July 2017

1 reference